Phase 4
Completed N=23
Effect of Cycloset on Glycemic Control When Added to Glucagon-like Peptide 1 (GLP-1) Analogue Therapy
Source: ClinicalTrials.gov NCT02299050 ↗Enrolled (actual)
23
Serious AEs
0.0%
Results posted
Jun 2019
Primary outcomePrimary: HbA1C — 8.3; 7.7 mmol/mol
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
Purpose This study will examine the effect of the addition of Cycloset upon glucose metabolism (glycemic control including post prandial glucose metabolism) in individuals with inadequately controlled (HbA1c 7.5-10.0) type 2 diabetes (T2DM) who are already on Bydureon (exenatide once weekly) or Victoza (liraglutide once daily) as part of their standard care.
Both a mechanistic rationale and empirical experimental evidence implicate a beneficial interaction between bromocriptine and the incretin mimetics (GLP-1 analogs) upon postprandial hyperglycemia in insulin resistant states. One of the actions of the incretin mimetics such as the GLP-1 analogs is to stimulate postprandial beta cell insulin secretory response to plasma glucose (see drug labeling information; www.fda.gov). Thus the combination of Cycloset that is working as a post prandial insulin sensitizier with therapies that increase post prandial insulin would be expected to provide complimentary glucose lowering effects. To date, however, no such studies investigating the interactive effects of a GLP-1 analog and Bromocriptine-QR (QR=extended release) (Cycloset) have been conducted in humans.
Condition - Type 2 Diabetes. Intervention - Cycloset. Phase - Phase 4
Study Type: Interventional Study Design: Treatment, Single Group Assignment, Open Label, N/A, Safety/Efficacy Study
Official Title: Effect of Cycloset on Glycemic Control in Type 2 Diabetic Patients Inadequately Controlled on GLP-1 Analogue Therapy
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY HbA1C |
8.3; 7.7 | — |
| PRIMARY Glucose Metabolism During Mixed Meal Tolerance Test |
1.1; 0.7 | — |
| SECONDARY Endothelial Function, |
54; 51 | — |
| SECONDARY Body Composition |
88.1; 87.1 | — |
| SECONDARY Percentage Body Fat |
39.1; 39.3 | — |
| SECONDARY Blood Pressure |
134; 126; 78; 73 | — |
| SECONDARY Mean Arterial Blood Pressure |
97; 90 | — |
| SECONDARY Arterial Stiffness (AS) |
19.8; 16.2 | — |
Eligibility Criteria
Inclusion Criteria
- Type 2 diabetes male or female subjects between the ages of 30 and 70 years of age, inclusive, at Screening
- BMI = 24-40 kg/m2
- HbA1c = 7.5-10.0%
- Stable body weight (±3-4lbs) over the preceding 3 months
- Subjects currently receiving a stable dose of exenatide (2mg/week) or liraglutide (1.2-1.8 mg/day) for at least 90 days prior to determination of baseline HbA1C and eligibility for enrollment in the study protocol.
- Subjects with a daytime feeding/night time sleeping schedule
- Subjects with no evidence of major organ system disease as determined by physical exam, history, and screening laboratory data
- Women must be of non-childbearing potential as defined by one of the following:
- Women >45 and 60 years of age
- Females of childbearing potential with a negative pregnancy test at Screening and Treatment visits, using one of the following forms of contraception for the duration of participation in the study (i.e., until Follow-up 7-14 days post last dose): Oral contraceptive, Injectable progesterone, subdermal implant, spermicidal foam/gel/film/cream/suppository, diaphragm with spermicide, copper or hormonal containing IUD (intrauterine device), sterile male partner vasectomized > 6 month pre-dosing
- Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study
- Subjects must be willing and able to comply with scheduled visits, treatment, laboratory tests and study procedures.
Exclusion Criteria
- Recent (i.e., within three (3) months prior to Screening) evidence or medical history of unstable concurrent disease such as: documented evidence or history of clinically significant hematological, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, immunological, or clinically significant neurological disease.
- No history of T2DM
- BMI of less 24 and greater 40 kg/m2
- Unstable body weight (change of greater than ±3-4lbs over the preceding 3 months
- Subjects not currently receiving exenatide or liraglutide
- Subjects participating in an excessively heavy exercise program
- Subject with a feeding/sleeping schedule different from a daytime feeding/night time sleeping schedule
- Subjects taking medications known to alter glucose metabolism (with the exception of metformin and/or pioglitazone) or which effect brain neuro synaptic function are excluded.
- Subjects with evidence of major organ system disease as determined by physical exam, history, and screening laboratory data
- Pregnant subjects or subjects unwilling to use birth control during their study enrollment
- Blood donation of approximately 1 pint (500 mL) within 8 weeks prior to Screening 12. Subjects that are allergic to bromocriptine or any of the other ingredients in Cycloset, or take ergot medicines, breastfeeding or have history of syncope or Type 1 diabetes mellitus
- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results that, in the judgment of the investigator, would make the subject inappropriate for entry into this study subjects of reproductive potential
Data sourced from ClinicalTrials.gov (NCT02299050). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.